US Pharma MarketingLilly’s dealmaking spreads the wealth among a broad set of biotech venture investors
Lilly Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s changing…
At least 50 different venture investors have benefited from Eli Lilly’s dealmaking this year, sending early investment dollars back into the startup ecosystem.
On Monday, Lilly announced its 13th acquisition of the year, up to ...
Source: Endpoints News